ArticleZeitschrift fur Rheumatologie2012
[Biologicals for children and adolescents in the treatment of rheumatic diseases].
Article in Zeitschrift fur Rheumatologie, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following pharmacolegal measures several biologic agents have been tested in children and adolescents with rheumatic diseases, mainly juvenile idiopathic arthritis (JIA), in controlled trials and have been introduced into treatment algorithms. This was achieved by international research cooperation and after introduction of well-defined criteria for disease entities, disease activity, improvement and deterioration. Etanercept, adalimumab, abatacept, tocilizumab and canakinumab have obtained limited licenses. Etanercept is the longest available biologic agent. Etanercept or adalimumab are the treatment of choice when methotrexate is not sufficient or toxic in children with polyarthritis. Tocilizumab is given to patients with systemic JIA when glucocorticoids fail or become toxic. These and other biologic agents including anakinra and rituximab are effectively applied also off label; however, there is a lack of long-term studies. These drugs should be prescribed only by pediatric rheumatologists.
Indexed as
Identifiers
22930109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.